Evaluation of a Multimodal Neuroimaging Method for Diagnosis in Parkinsonian Syndromes

Study Overview
=================
Brief Summary
-----------------
Based on previous promising results, the next step for the validation of a multimodal MRI method in diagnosis and follow up of patients reached by parkinsonian syndromes is (i) to test whether the multimodal neuroimaging is able to discriminate at the individual level, patients with multiple system atrophy parkinsonism (MSA) and patients with idiopathic Parkinson's disease (PD) (ii) to determine whether the method is sensitive to measure changes over time for the two diseases, according to imaging, neuropsychological and other clinical data. Patients will be compared with healthy controls.

Detailed Description
-----------------
30 patients with PD, 30 patients with MSA and 30 healthy controls will be examined in a 3Tesla MRI. The aim of our project is to demonstrate that our multimodal MRI method can discriminate both diseases with a similar clinical presentation and monitor the progress of the disease. CIC's expertise in recruitment and assessment of patients, and the powers of the INSERM U825 in terms of development and processing in neuroimaging guarantee the feasibility of the project and its successful completion.

Official Title
-----------------
Evaluation and Validation of a Multimodal MRI Neuroimaging Method: Application to Differential Diagnosis and Disease Progression in Parkinsonian Syndromes

Conditions
-----------------
Parkinson's Disease, Multiple System Atrophy

Intervention / Treatment
-----------------
* Other: MRI acquisition
* Behavioral: behavioral evaluations


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: informed consent signed right handed patients Mini Mental Score > 22 no other neurological disease than Parkinson's Disease (PD) or Multiple System Atrophy (MSA) non-demented patients reached by PD or MSA (according to diagnosis criteria from UK PD Brain Bank and from Gilman and colleagues, 1998, for PD and MSA respectively) for PD patients only : Hoehn and Yahr score from 2 to 3 Exclusion Criteria: claustrophobia contraindications to MRI (cardiac or auditive prothesis, pacemakers, cerebral clip, stimulating electrodes) pregnant women major neuropsychiatric disease refusal to be informed in case of cerebral anomaly detected during MRI acquisition uncompensated thyroid deficit

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients with Parkinson's Disease<br>Patients with PD will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned) | Other: MRI acquisition<br>* MRI acquisitions<br>Behavioral: behavioral evaluations<br>* Evaluations about motor abilities, sleep, cognition and lifestyle<br>|
| Experimental: Patients with MSA<br>Patients with MSA will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned) | Other: MRI acquisition<br>* MRI acquisitions<br>Behavioral: behavioral evaluations<br>* Evaluations about motor abilities, sleep, cognition and lifestyle<br>|
| Experimental: Controls<br>30 healthy controls will be submitted to an MRI acquisition and to behavioural evaluations in a sole visit | Other: MRI acquisition<br>* MRI acquisitions<br>Behavioral: behavioral evaluations<br>* Evaluations about motor abilities, sleep, cognition and lifestyle<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary outcome measure to discriminate individual patients and patients with MPI and AMS through multimodal MRI isolating multiparametric spatial signature resulting from a combination of markers in multimodal imaging. |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correlate MP and MSA disease severity with extracted multimodal MRI biomarkers in whole brain |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
differential diagnosis, multimodal MRI, Parkinson's Disease, Multiple System Atrophy